Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
90.42
-1.49 (-1.62%)
May 30, 2025, 4:00 PM - Market closed
Revvity Employees
Revvity had 11,000 employees as of December 29, 2024. The number of employees decreased by 500 or -4.35% compared to the previous year.
Employees
11,000
Change (1Y)
-500
Growth (1Y)
-4.35%
Revenue / Employee
$251,806
Profits / Employee
$26,055
Market Cap
10.66B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 11,000 | -500 | -4.35% |
Dec 31, 2023 | 11,500 | -5,200 | -31.14% |
Dec 31, 2022 | 16,700 | 0 | - |
Dec 31, 2021 | 16,700 | 2,700 | 19.29% |
Dec 31, 2020 | 14,000 | 1,000 | 7.69% |
Dec 31, 2019 | 13,000 | 500 | 4.00% |
Dec 31, 2018 | 12,500 | 1,500 | 13.64% |
Dec 31, 2017 | 11,000 | 3,000 | 37.50% |
Dec 31, 2016 | 8,000 | 0 | - |
Dec 31, 2015 | 8,000 | 300 | 3.90% |
Dec 31, 2014 | 7,700 | 100 | 1.32% |
Dec 31, 2013 | 7,600 | 100 | 1.33% |
Dec 31, 2012 | 7,500 | 300 | 4.17% |
Dec 31, 2011 | 7,200 | 1,000 | 16.13% |
Dec 31, 2010 | 6,200 | -2,000 | -24.39% |
Dec 31, 2009 | 8,200 | 300 | 3.80% |
Dec 31, 2008 | 7,900 | -800 | -9.20% |
Dec 31, 2007 | 8,700 | 200 | 2.35% |
Dec 31, 2006 | 8,500 | 500 | 6.25% |
Dec 31, 2005 | 8,000 | -2,000 | -20.00% |
Dec 31, 2004 | 10,000 | 0 | - |
Dec 31, 2003 | 10,000 | -700 | -6.54% |
Dec 31, 2002 | 10,700 | -100 | -0.93% |
Dec 31, 2001 | 10,800 | -1,700 | -13.60% |
Dec 31, 2000 | 12,500 | 500 | 4.17% |
Dec 31, 1999 | 12,000 | -1,000 | -7.69% |
Dec 31, 1998 | 13,000 | -1,000 | -7.14% |
Dec 31, 1997 | 14,000 | -1,000 | -6.67% |
Dec 31, 1996 | 15,000 | 0 | - |
Dec 31, 1995 | 15,000 | -10,000 | -40.00% |
Dec 31, 1994 | 25,000 | -7,000 | -21.88% |
Dec 31, 1993 | 32,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
RVTY News
- 12 days ago - Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Business Wire
- 22 days ago - Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy - Seeking Alpha
- 4 weeks ago - Revvity to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Benzinga
- 4 weeks ago - Revvity beats quarterly estimates on steady demand for medical equipment - Reuters
- 4 weeks ago - Revvity Announces Financial Results for the First Quarter of 2025 - Business Wire
- 5 weeks ago - Revvity Board Declares Quarterly Dividend - Business Wire